Lixte Biotechnology Holdings Inc. terminated an exclusive license agreement with Taipei Medical University, effective Dec. 25.
The termination was due to the university's failure to file and seek approval from the U.S. FDA for an investigational new drug application to treat hepatocellular carcinoma using the company's licensed technology by Dec. 25.